{
    "nctId": "NCT02210663",
    "briefTitle": "A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors",
    "officialTitle": "A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Solid Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Dose-limiting toxicities of veliparib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed malignant solid tumor, and any of the following: \\* Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; \\* Subjects with BRCA-mutated breast cancer who have received prior chemotherapy with anthracycline and/or taxanes; \\* Subjects with deleterious mutations of BRCA with advanced solid tumors who have received available standard therapies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Life expectancy of greater than 12 weeks.\n* Adequate organ and marrow function\u00b7 Measurable or non-measurable disease.\n\nExclusion Criteria:\n\n* Major surgery and/or radiation within (\\<) 4 weeks prior to study enrollment.\n* Chemotherapy or hormone therapy within (\\<) 4 weeks prior to study enrollment except for mitomycin C and nitrosoureas, in which case it is 6 weeks.\n* Any investigational agents within (\\<) 4 weeks prior to study enrollment.\n* Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study enrollment.\n* Toxicities (with the exception of alopecia) from prior major surgery, radiation, or systemic chemotherapy have not recovered to less than grade 2.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}